Premature infants receiving ROP treatment show personal-social development delay

Premature infants treated for Type 1 retinopathy of prematurity (ROP) and aggressive ROP (A-ROP) with intravitreal bevacizumab (IVB) and intravitreal aflibercept (IVA) may experience delay in personal and social development compared to untreated infants, according to a study. The prospective-controlled study, encompassed 3 groups: those treated with intravitreal bevacizumab (IVB,...